Search results
Author(s):
Chris Wai Hang Lo
,
Yue Fei
,
Bernard Man Yung Cheung
Added:
3 years ago
SGLT2 Inhibitors in HFpEF
Author(s):
Brent Deschaine
,
Sahil Verma
,
Hussein Rayatzadeh
Added:
1 year ago
Article
Author(s):
Giuseppe Rosano
,
David Quek
,
Felipe Martínez
Added:
3 years ago
Heart failure (HF) is a shared chronic phase of many cardiac diseases, including ischaemic heart disease, chronic obstructive pulmonary disease and hypertension. It is characterised by structural or functional impairment of ventricular filling or ejection of blood from the heart.1–3 It is estimated that there are more than 37.7 million cases of HF globally and its prevalence is on the rise.2 HF…
View more
Author(s):
Muhammad Shahzeb Khan
,
Javed Butler
Added:
4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events…
View more
SGLT2i in HFpEF
Author(s):
Mauro Gori
,
Emilia D’Elia
,
Edoardo Sciatti
,
et al
Added:
1 year ago
Article
Author(s):
Thomas A Zelniker
,
Eugene Braunwald
Added:
3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the…
View more
Author(s):
Anjali Agarwalla
,
Jadry Gruen
,
Carli Peters
,
et al
Added:
2 years ago
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
HFpEF in Primary Care
Author(s):
Simon Stewart
,
Amy R Stewart
,
Laura Waite
,
et al
Added:
2 years ago
Article
Author(s):
Mitja Lainscak
Added:
3 years ago
The renin–angiotensin–aldosterone system (RAAS) is an essential regulatory component of cardiovascular homeostasis that exerts its actions through hormones, angiotensin II and aldosterone, which regulate vascular tone and blood pressure by causing vasoconstriction and renal sodium and water retention.1 Abnormalities in cardiac function in heart failure (HF) activate the RAAS and sympathetic…
View more